Latest News
- Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company
June 21, 2018 - Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm
June 15, 2018
Latest Presentations
MP Corporate Presentation
June 25, 2018
MP presentation at the Cowen and Company 38th Annual Health Care Conference
March 13, 2018
Products
Molecular Partners is advancing a growing pipeline of DARPin therapies for the treatment of severe or life-threatening diseases, with an initial focus on oncology and ophthalmology. Its most advanced oncology candidate, MP0250, is for the treatment of solid tumors and hematological malignancies. In ophthalmology, the most advanced candidate is abicipar in wet age-related macular degeneration (wet AMD). It has been licensed to Allergan and is being tested in two phase III trials.
We tailor each DARPin® therapy to target single or multiple disease pathways responsible for serious and complex diseases, all in a single medicine.
